Biomarker Testing in NSCLC: Best Practices for Personalized Medicine

Opinion
Video

Panelists discuss how the interpretation of HER2 IHC scores informs treatment decisions in NSCLC, including adherence to ASCO/CAP guidelines and strategies for managing equivocal results.

  • (Rohit asks Levy) How do you interpret HER2 IHC scores when determining treatment for patients with NSCLC? How does this influence your therapeutic decisions?
  • When applying HER2 scoring and considering ASCO/CAP guidelines in NSCLC, do you follow breast cancer scoring guidelines, or have you considered using gastric cancer scoring?
  • How do you interpret equivocal or borderline results? Are there any specific considerations or additional testing you recommend for this group?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos